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Abstract: Background: The increased cardiovascular morbidity and mortality observed in chronic
kidney disease (CKD) patients can be partly explained by the presence of carbamoylated lipoproteins.
Lipid profiles can be determined with infrared spectroscopy. In this paper, the effects of carbamoylation
on spectral changes of non-high-density lipoproteins (non-HDL) were studied. Methods: In the
present study, fasting serum samples were obtained from 84 CKD patients (CKD stage 3–5: n = 37 and
CKD stage 5d (hemodialysis): n = 47) and from 45 healthy subjects. In vitro carbamoylation of serum
lipoproteins from healthy subjects was performed using increasing concentrations of potassium
cyanate. Lipoprotein-containing pellets were isolated by precipitation of non-HDL. The amount of
carbamoylated serum non-HDL was estimated using attenuated total reflectance-Fourier transform
infrared (ATR-FTIR) spectroscopy, followed by soft independent modelling by class analogy analysis.
Results: Carbamoylation resulted in a small increase of the amide I band (1714–1589 cm−1) of the
infrared spectroscopy (IR) spectrum. A significant difference in the amide II/amide I area under the
curves (AUC) ratio was observed between healthy subjects and CKD patients, as well as between the
two CKD groups (non-dialysis versus hemodialysis patients). Conclusions: ATR-FTIR spectroscopy
can be considered as a novel method to detect non-HDL carbamoylation.
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1. Introduction
Carbamoylation is a post-translational modification, playing a role in chronic kidney disease
(CKD), comparable to the role of glycation in diabetes mellitus [1,2]. This non-enzymatic reaction is
characterized by a covalent binding of isocyanic acid to the amino group (either the epsilon amino
group of lysine residus or the N-terminal amino group) of amino acids, polypetides, and (lipo)proteins.
This post-translational molecular modification contributes to the molecular ageing of proteins. Isocyanic
acid is formed continuously in an equilibrium reaction with urea or by myeloperoxidase (MPO). MPO is
an enzyme (present in e.g., neutrophils, monocytes, and some tissue macrophages) that catalyzes the
oxidation of thiocyanate in the presence of hydrogen peroxide, producing isocyanate at inflammation
sites (e.g., atherosclerotic plaques) [3]. Plasma isocyanic acid concentrations increase with a declining
kidney function [4].
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An increased cardiovascular morbidity and mortality (10–30 times higher than in the general
population) has been reported in the end-stage renal disease (ESRD) population [5], which can be
partly attributed to the influence of carbamoylated lipoproteins [6]. In renal failure, dyslipidemia
contributes to a worsening kidney function. Proteinuria is accompanied by a marked elevation of
low-density lipoproteins (LDL) [7]. Due to its carbamoylation, LDL can exert its prothrombotic [8] and
atherosclerosis-prone effects by stimulating an increased adhesion of monocytes to endothelial cells [9],
by inducing endothelial dysfunction [6] and endothelial mitotic cell death [10], and by promoting
smooth muscle proliferation [11]. Carbamoylated LDL (cLDL) has been identified as the most abundant
modified LDL isoform in human blood, which is also present in healthy individuals [12]. It is generated
by carbamoylation of apolipoprotein B, the protein component of the LDL particle [13]. CKD is also
associated with decreased serum high-density lipoprotein (HDL) concentrations. Carbamoylation
of HDL leads to a loss of the atheroprotective function of HDL, illustrated by an impaired ability to
promote cholesterol eﬄux from macrophages [14].
As carbamoylation is of major clinical importance, practical biomarkers for assessing
carbamoylation and lipoprotein carbamoylation, in particular, are needed. In the present study,
we explored the possibilities of infrared (IR) spectroscopy to assess non-HDL carbamoylation.
The advantages of IR spectroscopy to determine lipid profiles were already applied in the past [15].
In this paper, the effects of in vitro carbamoylation on spectral changes of non-HDL were studied.
Furthermore, non-HDL carbamoylation was investigated in healthy subjects, in non-dialysis (CKD
stage 3–5) as well as in hemodialysis patients (CKD stage 5d).
2. Materials and Methods
2.1. Study Participants
The control group consisted of 45 healthy subjects (median age: 28 years, interquartile range (IQR):
24–33 years), whereas the patient group consisted of 84 CKD patients (CKD stage 3–5: n = 37, median
age: 70 years, IQR: 56–75 years, and CKD stage 5d (hemodialysis): n = 47, median age: 67 years,
IQR: 56–75 years) of the Department of Nephrology, Ghent University Hospital. The approval of this
study was granted by the Ethical committee of the Ghent University Hospital (EC/2015/0932).
2.2. In Vitro Carbamoylation of Lipids
In vitro carbamoylation of lipids was achieved by adding increasing volumes of 0.5 mol/L
potassium cyanate (KOCN) solution (Sigma–Aldrich, St. Louis, MO, USA) in a phosphate buffered salt
(PBS) solution (0.1 mol/L, pH 8.0) (Sigma–Aldrich, MO, USA) to 1000 µL serum of healthy subjects.
Serum samples were carbamoylated using increasing concentrations of KOCN: 0 mmol/L, 20 mmol/L,
50 mmol/L, 80 mmol/L and 100 mmol/L. In vitro carbamoylation was carried out for 48 h at 37 ◦C (these
reaction conditions warrant a completeness of the reaction). Proof of carbamoylation was obtained by
verifying the electrophoretic mobility of lipoprotein fractions on a lipoprotein agarose electrophosis
(Hydragel 7, Sebia, Lisses, France) using a semi-automated HYDRASYS instrument (Sebia, Lisses,
France). The separated lipoproteins were stained with a lipid-specific Sudan black stain. The excess of
stain was removed with an alcoholic solution. The resulting electropherogram was evaluated visually.
2.3. In Vitro Oxidation
Oxidative stress is involved in the exacerbation of disease burden in CKD patients. In vitro
oxidation of serum was performed to reveal potential influences on the infrared spectrum. Ten samples
from the serum pool at the laboratory of clinical biology of the University Hospital in Ghent were
randomly selected. One milliliter of each sample was pooled. Before the oxidation process, non-HDL
were precipitated 5 times. According to a modified version of the method used by Coffey et al. [16],
oxidized non-HDLs were prepared by dialyzing 4 mL of the serum pool against 400 mL isotonic saline
(0.15 mol/L NaCl (VWR International, Haasrode, Belgium) dissolved in distilled water) containing
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60 µmol/L CuSO4 (copper(II)sulphate pentahydrate, Merck Eurolab, Leuven, Belgium) during one
hour. The dialysate was then changed to isotonic saline containing 0.5 mmol/L EDTA (BDH Chemicals,
Poole, England) and dialysis continued during one hour with changes of dialysate every 15 min.
After the oxidation process, non-HDL were precipitated 5 times from the oxidized serum pool.
2.4. Precipitation Procedure
All serum samples were centrifugated during 10 min at 3000× g. A precipitation reaction
was performed, in which non-HDL fats very-low-density lipoprotein (VLDL), intermediate-density
lipoprotein (IDL), lipoprotein(a), LDL and chylomicrons) were precipitated. 20 µL of a 13 mmol/L
sodium phosphotungstate hydrate solution (Sigma Aldrich St Louis, MO, USA) and 5 µL of 2 mol/L
MgCl2 (E. Merck KG, Darmstadt, Germany) were added to 200 µL serum. After vortexing, the samples
were centrifuged (10 min, 6000× g) (centrifuge 54515 D, Eppendorf, Hamburg, Germany) [17]. The
precipitate was subsequently dried for 48 h in an incubator. Completeness of the precipitation
reaction was assessed by lipid electrophoresis of the serum pre- and post-precipitation (5 samples
were precipitated in triplicate). The formed pellet was ground prior to analysis with attenuated total
reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy.
2.5. ATR-FTIR Analysis
All spectra were obtained by a Perkin Elmer Two ATR-FTIR spectrometer with the ATR accesory
and spectrum 10 software (Perkin Elmer, Waltham, MA, USA). Before and after each analysis, the 50 mm
ZnSE crystal was thoroughly cleaned with an alcoholic solution (Dax alcoliquid, Dialex biomedica,
Sweden). A background scan was taken after the complete evaporation of the alcoholic solution.
The lipoprotein powder was placed in contact with the surface of the crystal until complete covering.
The pressure applied to the sample was standardised at 100 gauche to obtain a good contact between
the sample and the crystal.
Three peaks were investigated: the carbonyl peak, the peak of the amide I band and the peak
of the amide II band. Within-run coefficients of variation (CV) and between-run CV were calculated.
The area under the curves (AUC) of the amide I and amide II bands were obtained by auto-labeling of
the peaks in the Perkin Elmer 10 software.
Spectra were analyzed using the software program SIMCA version 14.1 (Umetrics, Sartorius
Stedim Biotech, Umeå, Sweden). SIMCA (soft independent modeling of class analogy) was used to
identify the spectral changes due to carbamoylation of lipoproteins. By applying various spectral
filters, the noise was eliminated and the region of interest was selected. Data were normalized
using the standard normal variate (SNV) method and were converted to their second derivative.
The Savitsky-Golay algorithm allowed smoothing of the spectrum.
2.6. Routine Laboratory Measurements
After overnight fasting, blood samples were collected and centrifuged (10 min, 3000× g).
Urea, creatinine, albumin, triglycerides, total and HDL-cholesterol concentrations were assayed
using commercial reagents on a Cobas 8000 analyzer (Roche, Mannheim, Germany) [18]. The serum
concentration of apolipoprotein B was determined by immunonephelometry on a Behring BN II
nephelometer (Siemens, Marburg, Germany) [19]. The LDL-cholesterol concentration was estimated
using the Friedewald-formula [20]. The estimated glomerular filtration rate (eGFR) was calculated
with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [21].
2.7. Statistics
Statistical analyses were performed using MedCalc (MedCalc, Mariakerke, Belgium). Normality
of distributions was tested using the D’Agostino Pearson test. Data are expressed as median ± IQR
or mean ± standard deviation (SD). Differences between patient groups were assessed using the
Student’s t-test and the Kruskall–Wallis test. The effect of the biological parameters on the spectrum
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was evaluated using a multiple linear regression model. A p-value < 0.05 was considered a priori to be
statistically significant.
3. Results
3.1. In Vitro Carbamoylation
In vitro carbamoylation of lipoproteins in serum of healthy subjects was demonstrated by agarose
gel electrophoresis, which showed a progressive increase in electrophoretic mobility of lipoproteins
with increasing KOCN concentrations. The effectiveness of the precipitation reaction was illustrated by
the disappearance of the LDL and VLDL fraction on agarose gel electrophoresis. Serum samples with
the highest concentrations of KOCN showed a less efficient precipitation, probably due to an altered
protein structure, which could interfere with the precipitation process.
Carbamoylation was further investigated with ATR-FTIR spectroscopy. Figure 1 presents the
different IR spectra of the pellet of precipitated lipoproteins, urea, and KOCN. The visual spectrum of
urea and KOCN did not interfere with the IR spectra of the precipitated lipoproteins. The between-run
and within-run CVs for the detection of the carbonyl band (4.5% and 4.9%), the amide I band (4.9%
and 8.4%) and the amide II band (5.8% and 8.1%) were low.
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3.2. In Vivo Samples
Table 1 describes the general characteristics of the healthy subjects and the CKD patients. In the
in vivo part of the study, the findings of the in vitro study were compared with the CKD patients’
samples. The same spectral filters were applied and the amide I band was selected. There was a clear
distinction between the various groups (healthy subjects, patients with CKD stage 3–5 and CKD
5d patients).
Table 1. General characteristics of the healthy subjects and the chronic kidney disease patients.
Healthy Subjects CKD Stage 3, 4 or 5 CKD Stage 5d p
45 37 47
e ia age (years) 28 (24–33) 70 (56–75) 67 (56–75) <0.0001
% diabetes mellitus 0 30 32
Urea (mmol/L) 8.9 (7.8–9.9) 25.0 (18.7–37.5) 32.8 (28.5–40.1) <0.0001
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Albumin (g/L) 47.3 (45.0–50.0) 42.2 (40.3–44.5) 40.0 (36.2–42.9) <0.0001
Total cholesterol (mmol/L) 4.8 (4.3–5.5) 4.7 (3.7–5.5) 4.3 (3.7–5.8) NS
HDL cholesterol (mmol/L) 1.6 (1.3–2.0) 1.3 (1.0–1.6) 1.1 (0.9–1.5) <0.0001
LDL cholesterol (mmol/L) 2.7 (2.3–3.1) 2.3 (1.8–3.1) 2.4 (1.7–3.2) NS
Triglycerides (mmol/L) 1.0 (0.8–1.3) 1.7 (1.1–2.3) 1.4 (1.1–2.4) =0.0002
Apolipoprotein B (g/L) 0.8 (0.7–1.0) 0.8 (0.7–1.0) 0.8 (0.7–0.9) NS
NS = not significant.
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In addition, a significant difference in the amide II/amide I AUC ratio was observed between the
healthy subjects and the CKD groups (p < 0.0001) (Figure 3), as well as between the two CKD groups
(non-dialysis versus hemodialysis patients). A negative correlation was observed between the amide
II/amide I AUC ratio and the serum urea concentration (r = −0.63, p < 0.0001).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 6 of 9 
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Building on the in vitro model of carbamoylation, we showed that increasing serum KOCN
concentrations resulted in a reduced amide II/amide I AUC ratio. These amide bands in the IR
spectrum take part in the adding of the carbamoyl group on the amino group of the epsilon-amino
group of lysine and the terminal amino groups. The amide II/amide I AUC ratio reflects the observed
spectral changes due to carbamoylation. Significant differences of the amide II/amide I AUC ratio were
observed between healthy subjects, patients with advanced stages of CKD and hemodialysis patients.
As expected, this ratio showed a negative correlation with the serum urea concentration. This result
is supported by earlier findings, showing a similar regression coefficient between % carbamoylated
albumin and blood urea concentrations in ESRD subjects [26].
As demonstrated in the multiple regression model, age was identified as a minor predictor of
the amide II/amide I AUC ratio in comparison with apolipoprotein B and urea. Tissue accumulation
of carbamoylated proteins may be considered as a general hallmark of ageing, linking cumulative
metabolic alterations and age-related complications. In addition to the association with carbamoylation,
many other nonenzymatic posttranslational modifications occur during the biological life of proteins,
leading to protein molecular ageing [27].
A limitation of the present study is the fact that we did not perform liquid chromatography
tandem-mass spectrometry (LC-MS/MS) to objectify the amount of carbamoylation. This technique has
already been used for the detection of carbamoylated albumin [26], but not for carbamoylated non-HDL.
However, the relationship between the amide II/amide I AUC ratio and the KOCN concentration,
as well as its relationship with the serum urea concentration are very suggestive for the carbamoylation
process of non-HDL. A potential confounder could be the effect of diabetes mellitus, as the lysine
residues are susceptible to both carbamoylation and glycation by glucose [28]. However, previous
work of our research group showed no significant changes in the amide I and amide II band after
in vitro glycation of keratins in nail powder. After incubation of nail powders with respectively 1 mL
of 0.9% sodium chloride solution, 5% glucose solution and 10% glucose solution, a clear difference
in the area under the infrared peak was observed at wavenumber 1047 cm−2, a region characterized
by a characteristic carbohydrate absorption. This band was used for measuring the degree of keratin
glycation. No influence of glycation products was observed on the amide I and amide II bands [29].
In the CKD stage 3-5 group and in the CKD 5d group, there were respectively 29.7% and 31.3% diabetics
as compared to 0% in the group of healthy subjects. In addition, also oxidation may modify lipoproteins
in a similar way as it has been demonstrated by amino acid analysis that modification of lysine residues
occurs during LDL oxidation [30]. However as demonstrated in our in vitro experiments, oxidation
had no important influence on the reported results.
5. Conclusions
Carbamoylation is involved in the pathogenesis of various diseases (atherosclerosis, kidney
diseases, autoimmune diseases, infections, and thrombus formation) and has been identified as an
important risk factor for mortality in dialysis patients or in those with accelerated atherogenesis.
The development of novel tools to determine the degree of post-translational modification-derived
products is a demanding task. At this moment, the majority of potential carbamoylation biomarkers
can only be assessed by rather complex analytical methods, hampering their use in clinical practice [2].
In the present study, we have demonstrated that ATR-FTIR spectroscopy is an easy-to-use,
reagent-free, and cost-effective method. It is a non-destructive technique, consuming only a small
amount of sample [31]. Spectral changes of non-HDL were observed depending on a declining kidney
function. So, ATR-FTIR can be regarded as a new method for identification of carbamoylated non-HDL
in CKD patients.
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